Please login to the form below

Not currently logged in
Email:
Password:

paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated

Latest news

More from news
Approximately 9 fully matching, plus 118 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics